Allogene stamceltransplantatie in Nederland
Open

Resultaten bij patiënten van 16 jaar en ouder
Onderzoek
26-02-2009
A.V.M.B. (Ton) Schattenberg, Harry C. Schouten, Leo F. Verdonck, Roel Willemze, J. (Hans) van der Lelie, Peter C. Huijgens, Gustaaf W. van Imhoff, Anja van Biezen, Ronaldt Brand, A. (Ton) Hagenbeek, Theo de Witte en Jan J. Cornelissen

Allogeneic stem cell transplantation in the Netherlands in patients aged 16 years

Objective

To describe the activities in the field of allogeneic stem cell transplantation in the Netherlands in patients aged ≥ 16 years.

Design

Retrospective study.

Method

Data were collected from the Netherlands Stem Cell Transplant Registry – ‘TYPHON’. All transplant centres in the Netherlands reported their data to ‘TYPHON’. A general overview is given and data from the years 1967-1991 and from 1992-2002 are compared.

Results

The number of allogeneic transplants tripled between 1992-2002. The number of patients aged 45 years and older increased from 10 to 42%. The percentage of donors, other than HLA-identical siblings, doubled. The most frequent indications for transplantation were acute and chronic leukaemia. Results for leukaemia were far better if patients were transplanted in the early phase of the disease (first complete remission of the first chronic phase). Since the end of the nineteen-nineties the number of allogeneic stem cell transplants for chronic myeloid leukaemia has dropped due to the introduction of imatinib. An increasing number of patients were treated with reduced intensity pre-treatment conditioning.

Conclusion

Allogeneic stem cell transplantation is a curative treatment that is used increasingly in the Netherlands. Also older patients and patients without an HLA-identical sibling donor can be suitable candidates for transplantation.